Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers.
about
Purinergic receptor-mediated rapid depletion of nuclear phosphorylated Akt depends on pleckstrin homology domain leucine-rich repeat phosphatase, calcineurin, protein phosphatase 2A, and PTEN phosphatasesNovel Role for p110β PI 3-Kinase in Male Fertility through Regulation of Androgen Receptor Activity in Sertoli CellsTargeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapyThe Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma.Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice.Activity of any class IA PI3K isoform can sustain cell proliferation and survival.Enhancing DPYSL3 gene expression via a promoter-targeted small activating RNA approach suppresses cancer cell motility and metastasis.G-protein alpha-s and -12 subunits are involved in androgen-stimulated PI3K activation and androgen receptor transactivation in prostate cancer cells.Development of a peptide-drug conjugate for prostate cancer therapy.Nanomicellar TGX221 blocks xenograft tumor growth of prostate cancer in nude mice.Mechanisms of dihydrotestosterone action on resveratrol-induced anti-proliferation in breast cancer cells with different ERα status.p110δ PI3 kinase pathway: emerging roles in cancer.CD147 modulates androgen receptor activity through the Akt/Gsk-3β/β-catenin/AR pathway in prostate cancer cellsThe Modulation of Cardiac Contractile Function by the Pharmacological and Toxicological Effects of Urocortin2.P42 Ebp1 regulates the proteasomal degradation of the p85 regulatory subunit of PI3K by recruiting a chaperone-E3 ligase complex HSP70/CHIP.Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospectsPI-3 kinase p110β: a therapeutic target in advanced prostate cancers.Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges.Molecules in medicine mini-review: isoforms of PI3K in biology and disease.Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas.Characterization of a novel p110β-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells.P110β Inhibition Reduces Histone H3K4 Di-Methylation in Prostate Cancer.p110α and p110β isoforms of PI3K signaling: are they two sides of the same coin?Natural compound Alternol induces oxidative stress-dependent apoptotic cell death preferentially in prostate cancer cells.miR-376a suppresses proliferation and induces apoptosis in hepatocellular carcinoma.Casein kinase 2 inhibition attenuates androgen receptor function and cell proliferation in prostate cancer cells.Inhibition of the androgen receptor activity by Coprinus comatus substances.Alternol exerts prostate-selective antitumor effects through modulations of the AMPK signaling pathway.Androgen receptor-target genes in african american prostate cancer disparities.Knockdown of the cochaperone SGTA results in the suppression of androgen and PI3K/Akt signaling and inhibition of prostate cancer cell proliferation.RNAi-based functional selection identifies novel cell migration determinants dependent on PI3K and AKT pathways.TGX-221 inhibits proliferation and induces apoptosis in human glioblastoma cells.Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages.Knockdown Inhibits the Proliferation, Invasiveness, and Metastasis of Hepatocellular Carcinoma Cells and Sensitizes them to TRAIL-Induced Apoptosis
P2860
Q24337816-0E1FB928-4019-40D2-9A27-07F666197CC9Q28546072-0C3DAC4D-620B-4F89-B4A5-6B3535ED933EQ29248893-2AA1114B-5A25-4774-AF6E-9A996F11FF3DQ33607950-48DBF11D-897E-4F63-8240-07E3168F0467Q33832537-172628B1-E908-4C70-A753-E3600B3452D1Q33934457-37DB0441-1813-4D74-B68E-AA9E1BEF488CQ33952917-0612CE75-B21B-4096-B796-EA699C156B8CQ34519820-DFB51869-A57A-49F0-B78A-83C5BB856208Q35127176-A5BC6CD3-8E6D-4A83-B2D1-6B593E8E4DD5Q35184864-4DAE8461-4A0F-4E8C-A24C-4E520F2E8CBBQ35224405-0B6BCFD6-BA85-4BB1-A961-91FF7C9E0142Q36546496-7A3A96AF-1CBB-4FF2-B04E-3D87F1520A97Q36647928-8B1E5663-E191-42E1-B90D-35F928C06842Q37108042-17480203-FCC8-446C-8BAA-C9956FD94B0BQ37228131-6866B3BF-2794-4885-B321-CC90CBC19BFCQ37680192-9948E052-0151-4307-AD8D-C355FCD62244Q38212470-73A77F89-8E6F-402F-99F0-6B42583FC469Q38265574-52FF2B13-7DCD-4F4E-8313-3B8CADC2DCD4Q38413737-7AA08B07-4C18-4A2D-A279-A4939C555EC3Q38666875-85838032-2785-460A-AD50-4D3D3F689642Q38684394-137B1015-099A-48F8-900E-244376360477Q38699761-8998D8C4-FA9C-40C2-A485-CC3831916740Q38734609-35074735-B390-42EC-B7F9-24E56E2786C4Q38934741-2B8A37D8-7803-48C6-90C4-B1DEF3DFC636Q39009577-51E2439F-DF05-4F57-ADE3-59F531D7159DQ39334033-CB6A4FD1-571D-4147-8439-08AA1328A471Q39404093-3F1A3517-BCB9-45FF-85E1-5067D5F04ECAQ39461640-D0B0F1F4-92C5-489F-A384-6DF0D2006332Q39549271-A90FA489-EAC9-4C97-8EFF-FC01A0BFFF46Q42261015-3D05DFF6-CD75-4750-ADB5-A436F1465DB9Q42439577-107A7E67-EFAA-4B78-840E-D9BF62B83F7EQ42834164-70915049-56EE-4949-BC62-0A3712E697CAQ48011922-63A40018-ECBE-4CC5-A26F-F2233FE2146FQ55254953-FC39CAC0-D3A0-485C-BF9A-8D0D06A294D3Q56979446-E69847E0-E8D5-4CC9-8DD0-BBCEDA851ABC
P2860
Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phosphoinositide 3-OH kinase p ...... ogression in prostate cancers.
@en
Phosphoinositide 3-OH kinase p ...... ogression in prostate cancers.
@nl
type
label
Phosphoinositide 3-OH kinase p ...... ogression in prostate cancers.
@en
Phosphoinositide 3-OH kinase p ...... ogression in prostate cancers.
@nl
prefLabel
Phosphoinositide 3-OH kinase p ...... ogression in prostate cancers.
@en
Phosphoinositide 3-OH kinase p ...... ogression in prostate cancers.
@nl
P2093
P2860
P356
P1433
P1476
Phosphoinositide 3-OH kinase p ...... ogression in prostate cancers.
@en
P2093
J B Thrasher
P F Terranova
P2860
P2888
P304
P356
10.1038/ONC.2008.91
P407
P577
2008-03-31T00:00:00Z
P5875
P6179
1016986517